HIV Infections Clinical Trial
Official title:
Brief Alcohol Intervention in HIV+ Women
The purpose of this study is to determine whether two brief counseling sessions reduce drinking and improve health outcomes in HIV-positive women who drink at heavy/hazardous levels. Also, the study seeks to compare hazardous drinking versus nonhazardous drinking women on a variety of alcohol, HIV and life quality outcome measures.
Heavy alcohol use negatively impacts HIV/AIDS in several important ways. It increases
HIV-risk behaviors, impairs the immune system and accelerates HIV disease progression. Heavy
alcohol use also interferes with HIV care compliance, including appointment attendance and
medication adherence.
Women are particularly important targets for alcohol use interventions. The threshold for
harmful alcohol effects is strikingly low in women, with two drinks per day placing women at
risk for negative health consequences. Heavy/hazardous alcohol use is less likely to be
detected in women receiving health services. Women may be less likely to seek and or engage
in alcohol treatment services, making nontraditional care settings particularly important for
reaching this population.
This proposal tests the utility of a brief alcohol intervention for HIV+ women delivered in a
medical setting. Hazardous/binge female drinkers will be identified in the Johns Hopkins
Hospital HIV clinic and will be randomized to brief intervention or standard care. The brief
intervention will include two sessions that review drinking patterns and behavior change
strategies as well as two telephone calls to reinforce session content. In addition, a
comparison group of nonhazardous drinking, HIV+ women will be recruited. Outcome measures
will include: alcohol/drug use, engagement in an on-site alcohol support group and other
substance abuse treatment services, HIV-risk behaviors, HIV disease markers and treatment
compliance, and psychiatric symptoms.
The investigators hypothesize that women who receive the brief intervention will report lower
mean weekly alcohol consumption and fewer heavy drinking episodes than women in standard
care. The investigators also predict that women who receive brief intervention will adhere to
their HIV medications and keep their health care appointments more consistently, and have
improved HIV-related health outcomes. Finally, the investigators hypothesize that
nonhazardous drinkers will have fewer psychiatric symptoms and better quality of life than
hazardous drinking women.
Comparison(s): Standard HIV care
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |